127.31
+1(+0.79%)
Currency In USD
| Previous Close | 126.31 |
| Open | 126.3 |
| Day High | 127.98 |
| Day Low | 125.13 |
| 52-Week High | 238 |
| 52-Week Low | 110.04 |
| Volume | 1.1M |
| Average Volume | 1.65M |
| Market Cap | 18.65B |
| PE | 12.58 |
| EPS | 10.12 |
| Moving Average 50 Days | 124.95 |
| Moving Average 200 Days | 150.35 |
| Change | 1 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $311.48 as of June 26, 2025 at a share price of $127.31. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $492.19 as of June 26, 2025 at a share price of $127.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
GlobeNewswire Inc.
Yesterday at 11:30 AM GMT
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
GlobeNewswire Inc.
Jun 18, 2025 11:30 AM GMT
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the potential of omaveloxolone to address the critical
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
GlobeNewswire Inc.
May 27, 2025 11:30 AM GMT
Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertiseCAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a p